CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 152 enrolled
Drug / intervention
RSV vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06077149
NCT06077149Phase 4Completed
CompareCT.gov

A Comparison of Immunogenicity of Licensed RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) to Community-dwelling Older Adults

University of Rochester·interventional·Posted Oct 11, 2023·Updated Oct 27, 2025

In Brief

A Phase 4 clinical trial evaluating RSV vaccine for Respiratory Syncytial Virus (RSV). Completed, enrolled 152 participants across 1 site.

Detailed Summary

This clinical trial is studying the newly licensed RSV vaccines in adults over age 60 years living in long-term care facilities (nursing homes) by comparing the immune response to their vaccine to adults over age 60 years living in the community.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus (RSV)
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedOct 11, 2023
Enrollment StartNov 7, 2023
Primary CompletionNov 1, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 2.7 years ago

Interventions

RSV vaccinebiological

All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle. Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally